Doer Bio

Zhejiang Doer Biologics Co., Ltd. (Doer Bio) is a clinical-stage biopharmaceutical company focused on the discovery and development of multi-domain, multi-specific biotherapeutics to address unmet medical needs in metabolic diseases and oncology. The company leverages several proprietary platform technologies, including MultipleBody® for multi-targeting, AccuBody® for precision cancer therapy, SMART-VHHBody, and xLONGylation® for half-life extension. Its lead candidate, DR10624, is a first-in-class tri-specific agonist targeting FGF21R, GCGR, and GLP-1R, currently in Phase 3 development for severe hypertriglyceridemia (SHTG) and Phase 2 for metabolic dysfunction-associated steatohepatitis (MASH). Doer Bio operates as an independent subsidiary of Huadong Medicine, which acquired a 75% stake in the company in 2021.